Literature DB >> 26700665

Note of the methodological flaws in the paper entitled "Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis".

Ting-Ting Wang1, Jin-Mei Li1, Dong Zhou2.   

Abstract

With great interest, we read the paper "Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis" (by Chen PQ et al.) [1], which has reached important conclusions about the relationship between polymorphisms in interleukin (IL)-4/IL-13 pathway genes and glioma risk. Through quantitative analysis, the meta-analysis found no association between IL-4/IL-13 pathway genetic polymorphisms and glioma risk (Chen et al. in Tumor Biol 36:121-127, 2015). The meta-analysis is the most comprehensive study of polymorphisms in the IL-4/IL-13 pathway and glioma risk. Nevertheless, some deficiencies still exist in this meta-analysis that we would like to raise.

Entities:  

Keywords:  Glioma; IL-4/IL-13; Meta-analysis; Polymorphisms

Year:  2015        PMID: 26700665     DOI: 10.1007/s13277-015-4570-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies.

Authors:  Lin-Bo Gao; Xin-Min Pan; Li-Juan Li; Wei-Bo Liang; Yi Zhu; Lu-Shun Zhang; Yong-Gang Wei; Ming Tang; Lin Zhang
Journal:  Breast Cancer Res Treat       Date:  2010-07-17       Impact factor: 4.872

2.  Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis.

Authors:  Peiqin Chen; Chao Chen; Kun Chen; Tao Xu; Chun Luo
Journal:  Tumour Biol       Date:  2014-12-04

3.  Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population.

Authors:  Mansour S Al-Moundhri; Mariam Al-Nabhani; Bassim Al-Bahrani; Ikram A Burney; Ali Al-Madhani; Shym S Ganguly; Said A Al-Yahyaee; Christopher S Grant
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.